Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis
The medication continues to improve insulin sensitivity, which can protect against the risk of developing diabetes or heart disease in the long run
Its a common misconception that certain medical histories automatically disqualify you from hormone therapy (HRT)
Get ready to discover the secrets of facial creams and unlock the potential for a glowing complexion
Every plan is personalized because every clients skin responds differently
[online] Tsermpini, E.E., Plemenita Ilje, A